Stock Research: pSivida

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

pSivida

NasdaqGM:EYPT US30233G2093
16
  • Value
    69
  • Growth
    4
  • Safety
    Safety
    17
  • Combined
    7
  • Sentiment
    60
  • 360° View
    360° View
    16
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for retinal diseases. They operate in the biopharmaceutical industry. The company's operations are global. In the last fiscal year, the company had a market cap of $687 million, profits of $40 million, revenue of $43 million, and 165 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 16 (better than 16% compared with alternatives), overall professional sentiment and financial characteristics for the stock pSivida are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for pSivida. The consolidated Sentiment Rank has a good rank of 60, which means that professional investors are more optimistic about the stock than for 60% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 69 or better than 69% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 17, meaning that the share price of pSivida is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 4. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
17 29 6 35
Growth
4 5 75 45
Safety
Safety
69 76 32 33
Sentiment
60 39 100 65
360° View
360° View
16 18 64 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
93 91 69 63
Opinions Change
50 56 88 50
Pro Holdings
n/a 8 84 76
Market Pulse
17 26 42 22
Sentiment
60 39 100 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
17 29 6 35
Growth
4 5 75 45
Safety Safety
69 76 32 33
Combined
7 21 18 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
26 26 26 26
Price vs. Earnings (P/E)
7 7 7 28
Price vs. Book (P/B)
31 64 9 46
Dividend Yield
1 1 1 1
Value
17 29 6 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
4 1 61 75
Profit Growth
10 6 64 37
Capital Growth
23 84 17 19
Stock Returns
46 7 100 61
Growth
4 5 75 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 52 18
Refinancing
58 69 37 65
Liquidity
1 10 17 33
Safety Safety
69 76 32 33

Similar Stocks

Discover high‑ranked alternatives to pSivida and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

TEGNA

NYSE:TGNA
Country: USA
Industry: Broadcasting
Size: Medium
Full Stock Analysis

PriceSmart

NasdaqGS:PSMT
Country: USA
Industry: Hypermarkets, Super Centers
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.